Synthesis and Bioevaluation of Thieno[2,3-d]pyrimidinone Derivatives as Potential Tumor Cell Growth Inhibitors

Table 2

Cytotoxicities of target compounds 6a–i against various cancer cell lines.

Entry	Compd. no.	In vitro cytotoxicity IC^a50 (𝜇M)
		HepG2^b	MCF-7^b	BCG-823^b
1	6a	>200	>200	>200
2	6b	14.96±0.9	78.88±2.7	45.01±1.3
3	6c	45.19±1.8	>200	>200
4	6d	108.9±1.7	164±3.5	146.7±3.2
5	6e	>200	>200	244.17
6	6f	>200	>200	>200
7	6g	>200	>200	>200
8	6h	>200	>200	>200
9	6i	>200	>200	>200
10	5-FU^c	86.09±1.6	100.08±2.4	77.33±1.1

aIC₅₀: Compound concentration required to inhibit tumor cell proliferation by 50%.
^bAbbreviations: HepG2: human hepatocellular liver carcinoma cell line; BCG-823: human gastric cancer cell line; MCF-7: human breast adenocarcinoma cell line.
^cUsed as a positive control.